Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rotigotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 12/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 10/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rotigotine SCHEMBL1088585 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL9405994 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL30200958 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL50425 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL2597402 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL2597403 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL29483747 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL30730591 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL15970012 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL14697993 | 0.94 | DRD2 (0.89) | DRD2DRD3DRD4DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-3925606-B1 | ROTIGOTINE STABILIZATION METHOD | HISAMITSU PHARMACEUTICAL CO (JP) | 2026-03-11 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| US-20250329454-A1 | DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS | CHASE THERAPEUTICS CORP (US) | 2025-10-23 | — | — | US | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| EP-4093383-B1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING ROTIGOTINE AND AT LEAST ONE NON-AMINE-RESISTANT SILICONE ADHESIVE | LUYE PHARMA SWITZERLAND AG (CH) | 2025-08-27 | — | — | EP | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| WO-2022266160-A1 | DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS | CHASE THERAPEUTICS CORPORATION (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-01 | — | — | US | claimed |
| WO-2022251306-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-01 | — | — | WO | claimed |
| EP-4093383-A1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING THE INGREDIENT ROTIGOTINE AND AT LEAST ONE NON-AMINE-RESISTANT SILICONE ADHESIVE | Luye Pharma Switzerland AG (CH) | 2022-11-30 | — | — | EP | claimed |
| EP-4084827-A1 | KINASES AS BIOMARKERS FOR NEURODEGENERATIVE CONDITIONS | Chase Therapeutics Corporation (US) | 2022-11-09 | — | — | EP | claimed |
| EP-3145502-B1 | TRANSDERMAL DELIVERY SYSTEM CONTAINING ROTIGOTINE | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2022-07-06 | — | — | EP | claimed |
| US-11311495-B2 | Fibre-free transdermal therapeutic system and method for its production | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-04-26 | — | — | US | claimed |
| EP-3970705-A1 | FILM FORMING SPRAY PLASTERS FOR DERMAL AND TRANSDERMAL APPLICATION OF SUBSTANCES CONTAINING COMPLEXING ADJUVANTS FOR MOLECULAR COMPLEXATION | Inclusion GmbH (DE) | 2022-03-23 | — | — | EP | claimed |
| US-20220062279-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA A/S (DK) | 2022-03-03 | — | — | US | claimed |
| EP-3586828-B1 | METHOD FOR PREPARING BIODEGRADABLE MICROSPHERES HAVING IMPROVED STABILITY AND STORAGE STABILITY | G2GBIO INC (KR) | 2022-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | DRD2 656/4885DRD3 1833/4885DRD4 2138/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | DRD2 3598/4885DRD3 3311/4885DRD4 3534/4885 |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | NLN, PDIA5, PRNP | DRD2 1999/4885DRD3 2172/4885DRD4 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.